article thumbnail

Research organisations partner to transform clinical trials

Drug Discovery World

The Duke Clinical Research Institute (DCRI) and Protas, led by Oxford University clinical trialist Professor Sir Martin Landray, will collaborate to develop new approaches to large randomised clinical trials.

article thumbnail

Clinical Trials For All to educate public about clinical research

Drug Discovery World

Educational campaign, Clinical Trials For All, has been launched to drive greater understanding, participation and diversity in clinical trials. Only 59% of Americans know about clinical research, 91% of Americans have never been invited to participate, and Black/African and Hispanic/Latino Americans are less than 12% of participants.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

UK dementia research gets £49.9 million funding boost

Drug Discovery World

Head of clinical trials at the University College London (UCL) Dementia Research Centre, Dr Cath Mummery, has been announced as the Director of a new network of dementia trial sites across the country. million of new funding to improve access to clinical trials and help accelerate the development of new treatments.

Research 251
article thumbnail

Phase II brain metastases trial advances after futility analysis 

Drug Discovery World

The Phase II NANOBRAINMETS trial of AGuIX has been validated by the Data Safety and Monitoring Board (DSMB) following a futility analysis scheduled after the enrolment and follow-up of 50% of patients in the study. A total of 96 patients have been randomised to date of the 134 scheduled in the study’s protocol.

Trials 130
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management.

article thumbnail

Five 2024 breakthroughs in cancer drug research

Drug Discovery World

The trial results also demonstrated an 81% reduction in risk of progression or death and 94% reduction in progression of brain metastases compared to Xalkori (crizotinib). The results of two ongoing Phase I/II clinical trials evaluating cancer immunotherapy epcoritamab, a T-cell engaging bispecific antibody, were shared at ASCO.

article thumbnail

Potentially game-changing schizophrenia drug enters Phase I trials

Drug Discovery World

A potential schizophrenia treatment, discovered at Vanderbilt University in Tennessee in the US, has been cleared by the US Food and Drug Administration for use in Phase I clinical trials. The post Potentially game-changing schizophrenia drug enters Phase I trials appeared first on Drug Discovery World (DDW).

Trials 300